Effect of citalopram on chest pain in patients with functional chest pain

Effect of citalopram on chest pain in patients with functional chest pain - Ci-FCP

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON50787

Enrollment

Registered

2021-07-21

Start date

2022-01-17

Completion date

Unknown

Last updated

2024-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

'functional chest pain' and 'chest pain with unkown origin'

Interventions

During the study period of twelve weeks, patients will either receive daily 20 mg of citalopram or a placebo.

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: * Written informed consent * Minimum age: 18 years * Functional chest pain according to Rome IV criteria * Ruled out cardiac origin of chest pain * ECG with corrected QT interval (QTc) within the normal range (

Exclusion criteria

Exclusion criteria: * Currently using antidepressants * Contraindication for the use of SSRI * Already tried antidepressants off-label to treat chest pain * Known allergy to citalopram * Severe and clinically unstable concomitant disease * Pregnant, lactating or fertile women (without contraception)

Design outcomes

Primary

Measure	Time frame
Global assessment of patient reported reduction in chest pain after 6 weeks of treatment.	—

Secondary

Measure	Time frame
Global assessment of patient reported reduction in chest pain after 12 weeks of treatment. Symptom severity and frequency Health status and quality of life (SF-36) Psychological comorbidity (HADS) Adverse events/side effects	—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)